Related Experiment Video
Updated: Jun 3, 2026
12:00
Investigating the Effects of Antipsychotics and Schizotypy on the N400 Using Event-Related Potentials and Semantic Categorization
Published on: November 19, 2014
EEG alterations during treatment with olanzapine
Detlef Degner1, Michael A Nitsche, Frank Bias
1Department of Psychiatry and Psychotherapy, Georg-August University of Goettingen, Goettingen, Germany. ddegner@gwdg.de
European Archives of Psychiatry and Clinical Neuroscience
|March 25, 2011
Summary
Olanzapine treatment can cause abnormal EEG changes in patients with schizophrenia, particularly at higher doses. Regular EEG monitoring is recommended for patients on olanzapine, especially those exceeding 20 mg daily.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Olanzapine is a widely used antipsychotic for schizophrenia.
- EEG alterations and their correlation with olanzapine dosage require further investigation.
Purpose of the Study:
- To investigate EEG alterations in patients treated with olanzapine.
- To examine the relationship between olanzapine dose, plasma concentration, and EEG changes.
Main Methods:
- Naturalistic observational study of 22 schizophrenia patients on olanzapine monotherapy.
- EEG and olanzapine plasma levels measured under steady-state conditions.
- Comparison of EEG findings between patients with and without abnormalities.
Main Results:
- 40.9% of patients exhibited pathological EEG changes after olanzapine treatment.
- Significantly higher olanzapine doses (24.4 mg/day vs. 12.7 mg/day) were observed in patients with EEG changes.
- Higher olanzapine plasma concentrations tended to correlate with EEG abnormalities.
Conclusions:
- EEG abnormalities are common during olanzapine treatment and are dose-dependent.
- EEG monitoring is advised for olanzapine dosages exceeding 20 mg/day.
- While indicative, EEG has limited predictive power for future epileptic seizures.
Related Concept Videos
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:26Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...